Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.62 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.62 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.62 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.62 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.62 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.62 |
| ▸ | APP | P05067 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 4/20 | 0.51 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7789578 | 1.00 | KLK5 (0.62) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7799008 | 1.00 | KLK5 (0.62) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7797841 | 1.00 | KLK5 (0.62) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9016587 | 1.00 | KLK5 (0.62) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9016579 | 1.00 | KLK5 (0.62) | KLK5PSEN1PSEN2APH1BNCSTN | |
| Oxalic Acid SCHEMBL7796361 | 0.98 | KLK5 (0.60) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7392856 | 0.92 | KLK5 (0.67) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1601944 | 0.90 | CTSS (0.55) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL720790 | 0.89 | KLK5 (0.62) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7305946 | 0.88 | ATM (0.62) | KLK5PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | claimed |
| US-7279582-B2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2007-10-09 | — | — | US | disclosed |
| US-20030100755-A1 | Retroviral protease inhibiting compounds | ABBVIE INC. | 2003-05-29 | — | — | US | disclosed |
| EP-0748801-B1 | 2-ISOXAZOLINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING RELATED DERIVATIVES FROM THE SAME | DAICEL CHEM (JP) | 2001-12-19 | — | — | EP | disclosed |
| US-6284767-B1 | AIDS; MIXTURE WITH ENZYME INHIBITOR | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| EP-0486948-B1 | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-0997459-A1 | Intermediates for preparing retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2000-05-03 | — | — | EP | disclosed |
| US-6018069-A | 2-isoxazoline derivative and process for producing the same and process for producing related derivatives from the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| US-5962692-A | 2-isoxazoline derivative and process for producing the same, and process for producing related derivatives from the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5914332-A | NOVEL COMPOUNDS FOR USE AS HIV PROTEASE INHIBITORS IN TREATING HIV AND AIDS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | disclosed |
| US-5750717-A | 2-isoxazoline derivative and process for producing the same, and process for producing related derivatives from the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5648497-A | Retroviral protease inhibiting compounds | ABBOTT LABORAOTRIES (US) | 1997-07-15 | — | — | US | disclosed |
| US-5616714-A | PYRIDYL, THIAZOLYL-SUBSTITUTED AMINO ACID DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-04-01 | — | — | US | disclosed |
| US-5597926-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0748801-A1 | 2-ISOXAZOLINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING RELATED DERIVATIVES FROM THE SAME | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-18 | — | — | EP | disclosed |
| US-5554783-A | (2R, 3R, 4S, 5S)-3-ACETOXY-2,5-BIS/BENZYLOXYCARBONYLAMINO/ -4-BROMO-1,5-DIPHENYLHEXANE | ABBOTT LABORATORIES (US) | 1996-09-10 | — | — | US | disclosed |
| US-5541334-A | TREATING HIV | ABBOTT LABORATORIES (US) | 1996-07-30 | — | — | US | disclosed |
| US-5354866-A | Treating HIV infections | ABBOTT LABORATORIES (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0486948-A2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100755-A1 | Retroviral protease inhibiting compounds | SERPINB1, PREP, TMPRSS15 | KLK5 1558/4885PSEN1 211/4885PSEN2 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.